Equity Profile

IMVT

Immunovant, Inc.

Health CareBiotechnology$6.4B

May20Wed

Post-Earnings Recap

ReportedQ4-2026Pre-Market7:00 AM EDT

Immunovant, Inc. Misses on EPS, Stock Up 35.26%

Metric	Actual	Expected	Surprise
EPS	$-0.73	$-0.63	-21.06%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Immunovant, Inc. Misses on EPS, Stock Up 35.26%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.73	$-0.63	-21.06%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Immunovant's earnings report showed a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock surged by over 35%, indicating that investors may have reacted positively to other aspects of the company's performance or potential. The lack of revenue and guidance details leaves some uncertainty about future performance.

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

$-0.63

Revenue

While no revenue is expected this quarter, any updates on future revenue potential will be closely watched.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases. With a market cap of $5 billion, it operates in the health care sector, which is currently seeing increased interest due to advancements in medical treatments and a growing demand for innovative therapies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.82%

Avg Stock Reaction

+4.85%

Last Quarter Recap

In Q3-2026, Immunovant reported an EPS of $-0.61, which was better than the expected $-0.72, resulting in a positive stock reaction of +12.43% the following day. The company continues to focus on its pipeline of therapies.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Immunovant to report a loss this quarter, but there is hope for a surprise given the company's recent performance. The stock has shown volatility around earnings, which could lead to significant price movements.

Bull Case

If Immunovant beats EPS expectations, it could signal strong operational management and potentially boost investor confidence, leading to a positive stock reaction.

Bear Case

A miss on EPS could reinforce concerns about the company's financial health and lead to a negative stock reaction, especially given the lack of revenue expectations.

Key Metrics to Watch

EPS

$-0.63

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue potential will be closely watched.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.63?

A positive surprise could indicate improved operational efficiency and boost investor sentiment.

What updates can the company provide regarding its pipeline and future revenue potential?

Any insights into upcoming products or partnerships could significantly impact future revenue expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Immunovant's ability to improve its EPS, as recent operational efficiencies have not been fully recognized.

Supporting Evidence

The company has a history of surprising on EPS, with a 38% beat rate in recent quarters.

Options pricing suggests a larger move than historical averages, indicating potential for a surprise.

Insider selling could reflect a strategic repositioning rather than a lack of confidence.

Key Risk

If the EPS comes in better than expected, it could shift the narrative around the company's financial health.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Immunovant can turn around its losses and provide a clearer path to profitability.

Bull Confirmed If

An EPS of better than $-0.53 would confirm the bull case and suggest operational improvements.

Bear Confirmed If

An EPS worse than $-0.73 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±14.5%

Historical Avg

±9.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±14.5% while IMVT has averaged ±9.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

52.9%

Calls (43K)P/C Ratio: 0.06Puts (3K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$844,584.68

28,514 sh

2 insiders

Net

$844,584.68

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerGirao Tiago
$763,011.20

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunovant beats expectations, history suggests a positive reaction of about +4.5%, confirming that the company is on the right track.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around -1.18%, reflecting ongoing concerns about the company's financial stability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of therapies and their expected launch timelines.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Immunovant's products.
4Discussion on any partnerships or collaborations that could enhance revenue.
5Guidance on future financial expectations and milestones.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Baidu, Inc.

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

$-0.63

Revenue

While no revenue is expected this quarter, any updates on future revenue potential will be closely watched.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.82%

Avg Stock Reaction

+4.85%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Immunovant beats EPS expectations, it could signal strong operational management and potentially boost investor confidence, leading to a positive stock reaction.

Bear Case

A miss on EPS could reinforce concerns about the company's financial health and lead to a negative stock reaction, especially given the lack of revenue expectations.

Key Metrics to Watch

EPS

$-0.63

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue potential will be closely watched.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of $-0.63?

A positive surprise could indicate improved operational efficiency and boost investor sentiment.

What updates can the company provide regarding its pipeline and future revenue potential?

Any insights into upcoming products or partnerships could significantly impact future revenue expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Immunovant's ability to improve its EPS, as recent operational efficiencies have not been fully recognized.

Supporting Evidence

The company has a history of surprising on EPS, with a 38% beat rate in recent quarters.

Options pricing suggests a larger move than historical averages, indicating potential for a surprise.

Insider selling could reflect a strategic repositioning rather than a lack of confidence.

Key Risk

If the EPS comes in better than expected, it could shift the narrative around the company's financial health.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Immunovant can turn around its losses and provide a clearer path to profitability.

Bull Confirmed If

An EPS of better than $-0.53 would confirm the bull case and suggest operational improvements.

Bear Confirmed If

An EPS worse than $-0.73 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±14.5%

Historical Avg

±9.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±14.5% while IMVT has averaged ±9.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

52.9%

Calls (43K)P/C Ratio: 0.06Puts (3K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$844,584.68

28,514 sh

2 insiders

Net

$844,584.68

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerGirao Tiago
$763,011.20

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunovant beats expectations, history suggests a positive reaction of about +4.5%, confirming that the company is on the right track.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around -1.18%, reflecting ongoing concerns about the company's financial stability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of therapies and their expected launch timelines.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for Immunovant's products.
4Discussion on any partnerships or collaborations that could enhance revenue.
5Guidance on future financial expectations and milestones.